Gender and ethnicity intersect to reduce participation at a large European Hybrid HIV Conference

Supplementary Material

Supplement S1. Pre-structured observation tool used to gather information during the observed sessions.

Session Title:

Session Type:

| | Online/ in person | Gender | Ethnicity | Country | Profession |
|----------|-------------------|--------|-----------|---------|------------|
| Speakers | | | | | |
| Chairs | | | | | |
| Cildiis | | | | | |

| Questions | Mode (chat/ microphone) | Gender | Ethnicity | Country | Job | Answered? Yes/ no |
|-----------|----------------------------|--------|-----------|---------|-----|----------------------|
| 1 | | | | | | |
| 2 | | | | | | |
| 3 | | | | | | |
| 4 | | | | | | |
| 5 | | | | | | |
| 6 | | | | | | |
| 7 | | | | | | |
| 8 | | | | | | |
| 9 | | | | | | |

Supplement S2. Questions included in the post-conference survey

Q1. Age

- 18-25
- 26-30
- 31-34
- 35-40
- 41-50
- 51-60
- 60+

Q2. Gender

- Cis-Female (assigned female at birth and identify as female)
- Cis-Male (assigned male at birth and identify as male)
- Transfemale
- Transmale Non-binary / nonconforming
- Other
- Prefer not to say

Q3. Country of Residence

- White UK/White European/White Other
- Mixed or Multiple Ethnic Group
- Asian/ Asian British/ Asian Other
- Black African/ Black Caribbean/ Black British/Black Other
- Other Ethnic Group

Q4. Current role (tick all that apply)

- Allied Health Professional (nurse, physio, dietician, psychologist, health advisor)
- Medical Student
- Doctor in Training (non infectious disease trainee)
- Academic Trainee
- Infectious Disease/ GU Trainee
- Infectious Disease / GU Consultant
- Other Consultant (non ID)
- GP / Family Doctor / Primary Care Physician
- Senior Academic / Professor
- Social Scientist / Researcher
- Community Member

Q5. How would you describe your area of focus? (Tick all that apply)

- Clinical
- Epidemiology
- Public Health
- Social Science
- Basic Science
- Personal

Q6. Is English your first language?

- Yes
- No

If no, do you consider yourself fluent in English?

Q7. How many conferences have you attended in your career?

- 1-5
- 6-10
- 11-20
- 21+

Q8. Do you prefer to attend a conference virtually or in person?

- Virtually
- In person
- Hybrid
- Don't mind

Q9. How do you prefer to ask a question at a conference?

- In the app / online platform
- At the microphone / in person
- Combination of both
- I prefer not to ask questions

Q10. How many questions did you ask at EACS 2021 in total, via the microphone, the app or live chat? (approximately if you cannot recall)

- 0
- 1-3
- 4-6
- 7-9
- 10+

Q11. How did you ask your questions?

- N/A I did not ask a question
- Online
- In person/ at the microphone
- Mixture of both

Q12. If you asked a question online, did you post using your name or anonymously?

Q13. How many of your questions were picked or answered in total?

- 1
- 2
- 3
- 4
- 5
- 6+
- N/A

Q14. If you did not ask a question, or asked less than 4, why? Select all that apply.

- Not applicable I asked 4 or more questions
- I had nothing to ask
- I was worried about asking a stupid question
- I have had previous rejection or bad experience when asking a question
- I felt too junior
- I felt too senior
- I felt embarrassed / shy / nervous when public speaking
- I found the panel/speaker/chair intimidating
- I found the audience intimidating
- I didn't want to appear arrogant or critical of the speaker
- Lack of confidence in my knowledge
- Lack of confidence in the English language
- There wasn't enough time
- My boss was in the audience

Q15. Do you have any further comments about asking questions at conferences?

Supplement S3. Sessions attended at EACS by session type, the breakdown of male vs female panel members, the number of questions asked at each session and by whom, in relation to gender. Data presented as n (%).


| | | | 1 | | Quanti | 1 | 1 | | | |
|----|-------------------|--------------|-----------|----------|---------------|-----------|-----------|-----------|----------|-----------|
| | | | Male | Female | Questi ons | Questions | Questions | | Panel | Questions |
| | Session Name | Session Type | panel | panel | asked | male | female | % chair | Majority | majority |
| | Session Name | Session Type | parier | parier | askeu | male | Terriale | 70 CIIdli | wajonty | Пајопту |
| | Educational - | | | | | | | | | |
| 1 | dermatology | Educational | 2 (50%) | 2 (50) | 5 | 4 (80) | 1 (20) | 0% | 50/50 | male |
| | Individualized | | | | | | | | | |
| | Choices in | | | | | | | | | |
| | Antiretroviral | | | | | | | | | |
| | Therapy: Present | Industry | | | | | | | | |
| 2 | and Future | sponsored | 1 (33.3) | 2 (66.6) | 2 | 1 (50) | 1 (50) | 0% | female | 50/50 |
| | Oral Abstract | | | | | | | | | |
| | Session 1 - | Oral | | | | | | | | |
| 3 | Epidemiology | abstracts | 2 (33.3) | 4 (66.6) | 7 | 4 (57) | 3 (43) | 14% | female | male |
| | Best Posters 2 - | | | | | | | | | |
| | Social Sciences & | | | | | | | | | |
| 4 | Prevention | Poster | 4 (40) | 6 (60) | 12 | 4 (33.3) | 8 (66.6) | 50% | female | female |
| | | | | | | | | | | |
| | Updates in PrEP | | | | | | | | | |
| _ | implementation | | a (aa) | | | | | | | |
| 5 | and regimens | parallel | 3 (60) | 2 (40) | 14 | 8 (57) | 6 (43) | 14% | male | male |
| | Oral Abstract | | | | | | | | | |
| | Session 2 - | <u>.</u> | | | | | | | | |
| ~ | Current issues in | Oral | 4 (57) | 2 (42) | 45 | 10 (66 6) | 5 (22.2) | 26.60% | | and a |
| 6 | ART BHIVA | abstracts | 4 (57) | 3 (43) | 15 | 10 (66.6) | 5 (33.3) | 26.60% | male | male |
| | Symposium - | | | | | | | | | |
| | Improving | | | | | | | | | |
| | Outcomes for | | | | | | | | | |
| | People living | Industry | | | | | | | | |
| 7 | with HIV | sponsored | 2 (33.3) | 4 (66.6) | 9 | 3 (33.3) | 6 (66.6) | 44.40% | female | female |
| | Oral Abstract | | _ (00.0) | . () | - | - () | - () | | | |
| | Session 3 - | | | | | | | | | |
| | Comorbidities | | | | | | | | | |
| | and Co- | Oral | | | | | | | | |
| 8 | infections | abstracts | 3 (43) | 4 (57) | 17 | 12 (70.6) | 5 (29.4) | 29.40% | female | male |
| | Best Posters 4 - | | | | | | | | | |
| | Basic Science & | | | | | | | | | |
| 9 | HIV Cure | Poster | 1 (11.1) | 8 (88.9) | 14 | 8 (57) | 6 (43) | 71.40% | female | male |
| | Oral Abstract | | | | | | | | | |
| | Session 4 - | Oral | - (167) | a (a) | _ | . (| | | | |
| 10 | COVID19 | abstracts | 7 (100) | 0 (0) | 5 | 4 (80) | 1 (20) | 80% | male | male |
| | Best Posters 3 - | | | | | | | | | |
| | Co-morbidities & | | | | | | | | | |
| 11 | Co-infections | Poster | 6 (60) | 4 (40) | 14 | 9 (64) | 5 (36) | 28.50% | male | male |
| | ACT NOW: Long- | | | , | | - () | - () | / | | |
| | acting drugs | | | | | | | | | |
| 12 | against HIV | parallel | 3 (37.5) | 5 (62.5) | 16 | 12 (75) | 4 (25) | 18.75% | female | male |
| | | | · · · · / | 1 1 / | | · · · / | · · · / | | | |

Supplement S4. Sessions attended at EACS by session type, the breakdown of white vs other ethnicity panel members, the number of questions asked at each session and by whom, in relation to ethnicity. Data presented as n (%).


| | | | | Other | | | Questions | | panel | Questions | Q asked |
|----|-------------------------|-------------|------------|-----------|-----------|------------|-----------|---------|--------|-----------|-----------|
| | | Session | White | ethnicity | Questions | Questions | other | | % | majority | by other |
| | Session Name | Туре | panel | panel | asked | white | ethnicity | % chair | white | gender | ethnicity |
| | Educational - | | 4 | | | | | | | | |
| 1 | dermatology | Educational | 4 (100) | 0 (0) | 5 | 4(80) | 1(20) | 0% | 100% | male | 20% |
| - | Individualized | Educational | (100) | 0(0) | | 4(00) | 1(20) | 0/0 | 100/0 | maie | 2070 |
| | Choices in | | | | | | | | | | |
| | Antiretroviral | | | | | | | | | | |
| | | | | | | | | | | | |
| | Therapy: Present and | Industry | 3 | | | | | | | | |
| 2 | Future | | 3 (100) | 0 (0) | 2 | 2(100) | 0(0) | 0% | 100% | 50/50 | 0% |
| 2 | Oral Abstract | sponsored | (100) | 0(0) | Ζ | 2(100) | 0(0) | 0% | 100% | 50/50 | 0% |
| | Session 1 - | Oral | 6 | | | | | | | | |
| 2 | | | - | 0 (0) | - | 7(400) | 0(0) | 4.40/ | 4.000/ | | 00/ |
| 3 | Epidemiology | abstracts | (100) | 0 (0) | 7 | 7(100) | 0(0) | 14% | 100% | male | 0% |
| | Best Posters 2 - | | - | | | | | | | | |
| | Social Sciences | Desta | 7 | 2 (20) | 42 | 42(400) | 0(0) | 500/ | 700/ | (| 00/ |
| 4 | & Prevention | Poster | (70) | 3 (30) | 12 | 12(100) | 0(0) | 50% | 70% | female | 0% |
| | Updates in PrEP | | | | | | | | | | |
| | implementation | | 5 | | | | | | | | |
| 5 | and regimens | parallel | (100) | 0 (0) | 14 | 13(93) | 0(0) | 14% | 100% | male | 0% |
| | Oral Abstract | paraner | (100) | 0 (0) | | 10(00) | 0(0) | 11/0 | 100/0 | indie | 0,0 |
| | Session 2 - | | | | | | | | | | |
| | Current issues | Oral | 7 | | | | | | | | |
| 6 | in ART | abstracts | (100) | 0 (0) | 15 | 13(86.6) | 0(0) | 26.60% | 100% | male | 0% |
| - | BHIVA | 000010000 | (100) | 0 (0) | 10 | 10(0010) | 0(0) | 2010070 | 100/0 | indie | 0,0 |
| | Symposium - | | | | | | | | | | |
| | Improving | | | | | | | | | | |
| | Outcomes for | | | | | | | | | | |
| | People living | Industry | 5 | | | | | | | | |
| 7 | with HIV | sponsored | (83.3) | 1 (16.7) | 9 | 9(100) | 0(0) | 44.40% | 83.30% | female | 0% |
| | Oral Abstract | | (00.07 | = (====) | | -() | -(-) | | | | |
| | Session 3 - | | | | | | | | | | |
| | Comorbidities | | | | | | | | | | |
| | and Co- | Oral | 6 | | | | | | | | |
| 8 | infections | abstracts | (85.7) | 1 (14.3) | 17 | 17(100) | 0(0) | 29.40% | 85.70% | male | 0% |
| - | Best Posters 4 - | | . , | , -, | · · · · | ,/ | | | | | |
| | Basic Science & | | 6 | | | | | | | | |
| 9 | HIV Cure | Poster | (66.6) | 3 (33.3) | 14 | 14(100) | 0(0) | 71.40% | 66.60% | male | 0% |
| | Oral Abstract | | ,/ | <u> </u> | | (<i>i</i> | V-7 | | | | |
| | Session 4 - | Oral | 7 | | | | | | | | |
| 10 | COVID19 | abstracts | (100) | 0 (0) | 5 | 5(100) | 0(0) | 80% | 100% | male | 0% |
| | | | . , | | | . , | | | | | |
| | Best Posters 3 - | | | | | | | | | | |
| | Co-morbidities | | | | | | | | | | |
| 11 | & Co-infections | Poster | 9 (90) | 1 (10) | 14 | 13(93) | 1(7) | 28.50% | 90% | male | 7% |
| | ACT NOW: | | | | | | | | | | |
| | Long-acting | | | | | | | | | | |
| | drugs against | | 7 | | | | | | | | |
| 12 | HIV | parallel | (87.5) | 1 (12.5) | 16 | 14(37.5) | 1(6.25) | 18.75% | 87.50% | male | 6.25% |

| INNEL | | | ALL | | | | |
|------------------------|-----------|-----------|-----------|---------|-----------|-----------|------|
| COMPOSITION | FEMALE | MALE | MALE | | WHITE | WHITE | |
| n | 77 | 48 | 5 | | 82 | 48 | |
| Question type | | | | < 0.001 | | | 0.60 |
| Neutral | 37 (48.1) | 30 (62.5) | 1 (20.0) | | 46 (56.1) | 22 (45.8) | |
| Polite | 14 (18.2) | 4 (8.3) | 0 (0.0) | | 10 (12.2) | 8 (16.7) | |
| Shows under-confidence | 3 (3.9) | 3 (6.2) | 0 (0.0) | | 3 (3.7) | 3 (6.2) | |
| Shows over-confidence | 20 (26.0) | 11 (22.9) | 0 (0.0) | | 20 (24.4) | 11 (22.9) | |
| Unknown | 3 (3.9) | 0 (0.0) | 4 (80.0) | | 3 (3.7) | 4 (8.3) | |
| Mode | | | | 0.02 | | | 0.04 |
| Microphone | 2 (2.6) | 5 (10.4) | 0 (0.0) | | 2 (2.4) | 5 (10.4) | |
| Chat | 45 (58.4) | 33 (68.8) | 1 (20.0) | | 47 (57.3) | 32 (66.7) | |
| Chair/panel member | 30 (39.0) | 10 (20.8) | 4 (80.0) | | 33 (40.2) | 11 (22.9) | |
| Gender | | 1 | | 0.54 | | | 0.36 |
| Female | 44 (57.1) | 30 (62.5) | 4 (80.0) | | 48 (58.5) | 30 (62.5) | |
| Male | 33 (42.9) | 17 (35.4) | 1 (20.0) | | 34 (41.5) | 17 (35.4) | |
| Unknown | 0 (0.0) | 1 (2.1) | 0 (0.0) | | 0 (0.0) | 1 (2.1) | |
| Observed ethnicity | | | | 0.59 | | | 0.14 |
| White | 75 (97.4) | 43 (89.6) | 5 (100.0) | | 79 (96.3) | 44 (91.7) | |
| Black | 0 (0.0) | 1 (2.1) | 0 (0.0) | | 0 (0.0) | 1 (2.1) | |
| Asian | 1 (1.3) | 1 (2.1) | 0 (0.0) | | 2 (2.4) | 0 (0.0) | |
| Unknown | 1 (1.3) | 3 (6.2) | 0 (0.0) | | 1 (1.2) | 3 (6.2) | |
| Country | | | | 0.34 | | | 0.09 |
| UK | 26 (33.8) | 22 (45.8) | 0 (0.0) | | 24 (29.3) | 24 (50.0) | |
| Europe | 44 (57.1) | 22 (45.8) | 4 (80.0) | | 49 (59.8) | 21 (43.8) | |
| Outside EU | 4 (5.2) | 2 (4.2) | 1 (20.0) | | 6 (7.3) | 1 (2.1) | |
| Unknown | 3 (3.9) | 2 (4.2) | 0 (0.0) | | 3 (3.7) | 2 (4.2) | |
| Seniority | | | | < 0.001 | | | 0.01 |
| Professor | 28 (36.4) | 7 (14.6) | 2 (40.0) | | 29 (35.4) | 8 (16.7) | |
| Doctor / Senior | | | | | | | |
| academic | 34 (44.2) | 31 (64.6) | 0 (0.0) | | 38 (46.3) | 27 (56.2) | |
| Scientist / AHP / PhD | | | | | | | |
| student | 3 (3.9) | 0 (0.0) | 2 (40.0) | | 1 (1.2) | 4 (8.3) | |
| Non-medical | | | | | | | |
| professional | 9 (11.7) | 4 (8.3) | 1 (20.0) | | 11 (13.4) | 3 (6.2) | |
| Unknown / other | 3 (3.9) | 6 (12.5) | 0 (0.0) | | 3 (3.7) | 6 (12.5) | 1 |


Supplement S5. Characteristics of questions asked by panel composition. Data presented as n (%). PANEL MAJORITY ALL P MAJORITY ALL P




Supplement S6. Relationship between panel composition by gender and audience participation. Total 12 sessions: 1 all male, 7 majority (50% or more) female, 4 majority male.




Supplement S7. Relationship between panel composition by gender and audience participation. Total 12 sessions: 1 all male, 11 mixed.




Supplement S8. Relationship between panel composition by ethnicity and audience participation. Total 12 sessions: 6 all white, 6 majority white.





Supplement S9. Relationship between panel composition by gender and ethnicity and audience participation. Total 12 sessions: 1 all male all white, 2 majority female all white, 5 majority female majority white, 3 majority male all white, 1 majority male majority white.



Supplement S10. Questions answered in survey broken down by self-identified gender and ethnicity, as reported by the respondents of the online survey. Data presented as n, (%)

| Gender | | Ethnicity | | | | | | | | |
|------------|---|-------------|------------|------------|------------|------------|--|--|--|--|
| Male | Female | White | Black | Asian | Mixed | Other | | | | |
| | Have been to 21+ previous conferences | | | | | | | | | |
| 136, (60) | 130, (42.8) | 220, (54) | 4, (19) | 14, (39) | 18, (47.4) | 21, (48.8) | | | | |
| | Preference for Hybrid or Online (vs in-person or no preference) | | | | | | | | | |
| 60, (26) | 97, (32) | 124, (30.4) | 2, (9.5) | 16, (44.4) | 11, (29) | 10, (23.3) | | | | |
| | Preference for asking questions at the microphone (vs online) | | | | | | | | | |
| 38, (16.7) | 24, (7.9) | 51 (12.5) | 6 (28.6) | 3 (8.3) | 1 (2.6) | 6 (14) | | | | |
| | Asked 1 or more question at EACS 2021 | | | | | | | | | |
| 89, (39.2) | 106, (34.9) | 147, (36) | 11, (52.4) | 13, (36.1) | 15, (39.5) | 18, (41.9) | | | | |

Supplement S11. Barriers to asking questions at EACS 2021, broken down by self-identified gender and ethnicity, reported by respondents of the online survey. (Data removed for respondents who did not give gender or ethnicity) Data presented as n, %

| respondents who are in | Gende | r (Self- ified) | Ethnicity (Self-Identified) | | | | | |
|---|---------------|--------------------|-----------------------------|----------|--------------|--------------|--------------|--|
| | Male | Female | White | Black | Asian | Mixed | Other | |
| N/A (asked more than 4 questions) | 28, 8.5% | 19, 3.8% | 34, 5.2% | 4, 14.8% | 3, 6.1% | 2, 3.2% | 5, 8.2% | |
| I had nothing to ask | 102, 30.8% | 108, 21.8% | 159, 24.5% | 7, 25.9% | 15, 30.6% | 13, 20.6% | 20, 32.8% | |
| Worried about asking a stupid question | 27, 8.1% | 63, 12.7% | 71, 10.9% | 3, 11.1% | 5, 10.2% | 7, 11.1% | 6, 9.8% | |
| Previous rejection/bad experience | 2, 0.6% | 7, 1.4% | 6, 0.9% | 1, 3.7% | 0,0% | 1, 1.6% | 0, 0% | |
| I felt too junior | 17, 5.1% | 36, 7.2% | 42, 6.5% | 1, 3.7% | 4, 8.2% | 5, 7.9% | 2, 3.3% | |
| I felt too senior | 4, 1.2% | 1, 0.2% | 6, 0.9% | 0,0% | 0,0% | 0,0% | 1, 1.6% | |
| I felt embarrassed/ shy/ nervous speaking in public | 24, 7.5% | 60, 12.1% | 71, 10.9% | 1, 3.7% | 4, 8.2% | 6, 9.5% | 3, 4.9% | |
| I found the panel/ speaker/ chair intimidating | 2, 0.6% | 6, 1.2% | 5, 0.8% | 0,0% | 1, 2.0% | 2, 3.2% | 1, 1.6% | |
| I found the audience intimidating | 4, 1.2% | 11, 2.2% | 11, 1.7% | 0,0% | 1, 2.0% | 3, 4.8% | 1, 1.6% | |
| Didn't want to appear arrogant/ critical of the speaker | 20, 6.0% | 8, 1.6% | 25, 3.9% | 1, 3.7% | 2, 4.1% | 0,0% | 1, 1.6% | |
| Lack of confidence in my knowledge | 16, 4.8% | 36, 7.2% | 41, 6.3% | 5, 18.5% | 3, 6.1% | 5, 7.9% | 1, 1.6% | |
| Lack of confidence in English language | 28, 8.5% | 47, 9.5% | 63, 9.7% | 0,0% | 4, 8.2% | 6, 9.5% | 7, 11.5% | |

| There wasn't enough time | 47, 14.2% | 65, 13.1% | 83, 12.8% | 3, 11.1% | 5, 10.2% | 9, 14.3% | 11, 18.0% |
|-----------------------------|--------------|--------------|--------------|----------|----------|-------------|--------------|
| My boss was in the audience | 0,0% | 1, 0.2% | 1, 0.2% | 0,0% | 0,0% | 0,0% | 0,0% |